Share
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus bendamustine, and rituximab plus chlorambucil in front-line CLL therapy: The GO-CLLEAR Study by Czech CLL Study Group
LEUKEMIA & LYMPHOMA
Nemcova, L; Nekvindova, L; Spacek, M; Simkovic, M; Papajik, T; Brejcha, M; Lysak, D; Zuchnicka, J; Novak, J; Starostka, D; Poul, H; Vrbacky, F; Urbanova, R; Panovska, A; Plevova, K; Pospisilova, S; Hrobkova, S; Koritakova, E; Smolej, L; Doubek, M, 2020: Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus bendamustine, and rituximab plus chlorambucil in front-line CLL therapy: The GO-CLLEAR Study by Czech CLL Study Group. LEUKEMIA & LYMPHOMA 61, p. 57 - 59
CEITEC authors: